Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study.
Authors
Lamarca, AngelaMcCallum, Lynne
Nuttall, Christina
Barriuso, Jorge
Backen, Alison C
Frizziero, Melissa
Leon, Rebecca
Mansoor, Was
McNamara, Mairéad G
Hubner, Richard A
Valle, Juan W
Affiliation
Department of Medical Oncology , European Neuroendocrine Tumour Society (ENETS) Centre of Excellence, The Christie NHS Foundation Trust , Manchester , UKIssue Date
2018-07
Metadata
Show full item recordAbstract
Patients with advanced well-differentiated neuroendocrine tumours (Wd-NETs) are commonly treated with somatostatin analogues (SSAs). Some patients may develop SSA-related side effects such as pancreatic exocrine insufficiency (PEI).Citation
Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study. 2018, 12(7): 723-731 Expert Rev Gastroenterol HepatolJournal
Expert Review of Gastroenterology & HepatologyDOI
10.1080/17474124.2018.1489232PubMed ID
29923433Type
ArticleLanguage
enISSN
1747-4132ae974a485f413a2113503eed53cd6c53
10.1080/17474124.2018.1489232
Scopus Count
Collections
Related articles
- Chronic Use of Long-Acting Somatostatin Analogues (SSAs) and Exocrine Pancreatic Insufficiency (EPI) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Under-recognized Adverse Effect.
- Authors: Saif MW, Romano A, Smith MH, Patel R, Relias V
- Issue date: 2020
- EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
- Authors: Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA, ELECT Study Group *.
- Issue date: 2016 Sep
- Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.
- Authors: Chan DL, Ferone D, Albertelli M, Pavlakis N, Segelov E, Singh S
- Issue date: 2017 Sep
- Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.
- Authors: Martín-Richard M, Massutí B, Pineda E, Alonso V, Marmol M, Castellano D, Fonseca E, Galán A, Llanos M, Sala MA, Pericay C, Rivera F, Sastre J, Segura A, Quindós M, Maisonobe P, TTD (Tumores del Tracto Digestivo) Study Group.
- Issue date: 2013 Sep 20
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
- Authors: Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P, CLARINET Investigators.
- Issue date: 2014 Jul 17